Clinical meaning
Advanced cardiovascular management by the clinician requires integration of diagnostic data with evidence-based treatment guidelines to optimize patient outcomes. The ACC/AHA heart failure guidelines recommend quadruple therapy for HFrEF (EF ≤ 40%): renin-angiotensin system inhibition (ACEi/ARB/ARNI), evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), mineralocorticoid receptor antagonist (spironolactone/eplerenone), and SGLT2 inhibitor (dapagliflozin/empagliflozin) — each pillar addresses different neurohormonal pathways contributing to ventricular remodeling and disease progression. Lipid management follows the pooled cohort equations for ASCVD risk assessment, with high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) recommended for clinical ASCVD, LDL ≥ 190 mg/dL, diabetes with risk factors, or 10-year ASCVD risk ≥ 7.5%. Atrial fibrillation management integrates rate versus rhythm control strategies with stroke prevention using the CHA₂DS₂-VASc score to guide anticoagulation decisions, preferring DOACs over warfarin for non-valvular AF.